<!DOCTYPE html>
<html><head><style>table, th, td {border: 1px solid black;border-collapse: collapse;}</style></head>
<table colsep="0" frame="topbot" id="tbl1" trsep="0" xmlns="http://www.elsevier.com/xml/common/cals/dtd">
<label>
        Table 1
       </label>
<caption id="cap0015">
<simple-para id="tspara0010" view="all">
         Characteristics of the included studies.
        </simple-para>
</caption>

<tgroup cols="6">
<colspec colname="col1" colnum="1"/>
<colspec colname="col2" colnum="2"/>
<colspec colname="col3" colnum="3"/>
<colspec colname="col4" colnum="4"/>
<colspec colname="col5" colnum="5"/>
<colspec colname="col6" colnum="6"/>
<thead>
<tr trsep="1" valign="top">
<td xmlns="http://www.elsevier.com/xml/common/dtd">
           Reference ID
          </td>
<td xmlns="http://www.elsevier.com/xml/common/dtd">
           Study design
          </td>
<td xmlns="http://www.elsevier.com/xml/common/dtd">
           Sample size
          </td>
<td xmlns="http://www.elsevier.com/xml/common/dtd">
           Mean age (SD)
          </td>
<td xmlns="http://www.elsevier.com/xml/common/dtd">
           Definition of low-risk prostate cancer
          </td>
<td xmlns="http://www.elsevier.com/xml/common/dtd">
           Quality assessment
          </td>
</tr>
</thead>
<tbody>
<tr valign="top">
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Chen/2018/Singapore [
           
           ]
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Prospective cohort
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           19
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           65.4 (4.9)
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           prostate specific antigen (PSA) ≤10 ng/mL, Gleason score ≤6, clinical stage ≤ T2a)
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Fair
          </td>
</tr>
<tr valign="top">
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Alberts/2017/Netherlands [
           
           ]
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Prospective cohort
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           210
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           65.4#
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Gleason score 3 + 3
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Fair
          </td>
</tr>
<tr valign="top">
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Almeida/2016/Italy [
           
           ]
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Prospective cohort
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           73
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           63 (5.9)
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           1) men should have a histologically proven adenocarcinoma of the prostate, and they should be fit for possible curative treatment, be willing to attend the follow-up visits, and should not have received former therapy [
           
           ]; clinical stage T1c/T2 [
           
           ]; GS ≤ 6 [
           
           ]; ≤ 2 positive biopsy cores [
           
           ]; PSA ≤ 10 ng/mL [
           
           ]; PSAD ≤ 0.2 ng/mL/ml.
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Fair
          </td>
</tr>
<tr valign="top">
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Borkowetz/2017/Germany [
           
           ]
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Retrospective cohort
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           83
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           73#
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           ≤cT2c, ≤2 cores with proven cancer,
           <br/>
           Gleason score ≤6 (3 + 3), prostate specific antigen (PSA) density &lt;0.2 ng/mL2 and PSA &lt;10 ng/mL.
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Fair
          </td>
</tr>
<tr valign="top">
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Hamoen/2018/Netherlands [
           
           ]
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Prospective cohort
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           111
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           64#
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           PSA density &lt;0.2 ng/mL/ml, clinical stage cT1c–cT2c, and GS 3 + 3 and 2 positive biopsy cores at initial TRUSGB were
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Fair
          </td>
</tr>
<tr valign="top">
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Hashimoto/2012/Japan [
           
           ]
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Retrospective cohort
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           11
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           65#
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           NR
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Fair
          </td>
</tr>
<tr valign="top">
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Hsiang/2019/USA [
           
           ]
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Retrospective cohort
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           122
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           63#
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           grade group [GG] 1
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Fair
          </td>
</tr>
<tr valign="top">
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Osses/2020/Netherlands [
           
           ]
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Retrospective cohort
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           111
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           66#
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           ISUP grade 1
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Fair
          </td>
</tr>
<tr valign="top">
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Ploussard/2019/France [
           
           ]
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Retrospective cohort
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           143
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           64.4
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           GG 1, T1–T2 disease and PSA ≤ 10
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Fair
          </td>
</tr>
<tr valign="top">
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Schoots/2018/Netherlands [
           
           ]
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Prospective cohort
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           331
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           67#
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           (GS 3 + 3)
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Fair
          </td>
</tr>
<tr valign="top">
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Vos/2016/Canada [
           
           ]
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Prospective cohort
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           23
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           65
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Gleason score ≤ 6, and either clinical stage ≤ T2a or PSA ≤ 10 ng/mL.
          </td>
<td align="left" xmlns="http://www.elsevier.com/xml/common/dtd">
           Fair
          </td>
</tr>
</tbody>
</tgroup>
<legend>
<simple-para id="tspara0015" view="all">
         # = median, NR = not reported.
        </simple-para>
</legend>
</table>
</html>
